Published on 10 May 2024 on Zacks via Yahoo Finance
Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?
Investors are always looking for stocks that are poised to beat at earnings season and Black Diamond Therapeutics, Inc. BDTX may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Black Diamond Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for BDTX in this report.In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 41 cents per share for BDTX, narrower than the broader Zacks Consensus Estimate of a loss of 44 cents per share. This suggests that analysts have very recently bumped up their estimates for BDTX, giving the stock a Zacks Earnings ESP of +5.75% heading into earnings season.
Black Diamond Therapeutics, Inc. Price and EPS Surprise
